SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

   Biotech / MedicalNNVC - NanoViricides, Inc.


Previous 10 Next 10 
From: donpat6/4/2016 12:30:36 PM
   of 12856
 
Billions needed to combat Zika virus, possible vaccine by September

Susanna Heller

June 3, 2016

Yahoo News Now: Zika virus: NIAID director on the latest U.S. cases

The National Institutes of Health is “very aggressively pursuing” a potential vaccine to combat the Zika virus and hopes to have an early safety study of a vaccine by September 2016, said National Institute of Allergy and Infectious Diseases director Anthony Fauci, MD.

Fauci spoke with Yahoo guest anchor Debbye Turner Bell on Friday about the importance of President Obama’s outstanding request for $1.9 billion to combat the disease.

According to the CDC, there are currently 618 travel-associated cases of Zika in the continental U.S. and Hawaii. There are 162 confirmed cases of the virus in Florida, and 38 infected pregnant women in that state alone.

Without federally funded aid, Florida will face in impending Zika “disaster,” Florida Gov. Rick Scott warned.

The funding would be appropriated to several public health groups to combat the disease.

The NIH requires funding for basic and clinical research, such as understanding the virus’s implications for pregnancy and microcephaly in the fetus, Fauci said.

Fauci also said the NIH is actively pursuing the development of a vaccine for the virus, which they hope to be able to test by September 2016.

According to Fauci, women are the most susceptible to the infection in their first trimester, as they may not be aware of their pregnancy in its early stages. For that reason, the NIH proposes that all women of childbearing age are vaccinated prior to becoming pregnant.

The CDC would receive funds for surveillance, infection control, public health initiatives and mosquito control. He added that the CDC has sent employees to Brazil and Puerto Rico, among other South American countries where the virus is rampant, to assist in combatting it, Fauci said.

The extent to which the virus has spread in Brazil has caused many to speculate about the safety of the Olympic games, as they will be held in Rio de Janeiro this August.

U.S. Olympic cyclist Tejay Van Garderen withdrew from the Olympics on Thursday so as to avoid causing any complications to his wife’s pregnancy.

Fauci, however, does not advise athletes to pull out of the Olympics or canceling the games altogether. Instead, he recommends reading the CDC’s guidelines to prevent infection and sexual transmission of the virus.

“If you are pregnant or might be pregnant, you definitely should avoid going to an area where there is a Zika outbreak, including Brazil,” he added.

Zika, like Chikungunya and Dengue, is spread by the bite of an infected mosquito.

Zika, however, can be sexually transmitted and has been linked to complications with pregnancies and severe fetal neurological defects, including microcephaly.

An infected man can transfer the disease to a woman via unprotected sex or oral sex. There is no evidence that it has been transferred from a woman to man.

Fauci urged men to refrain from unprotected sex if they believe they have been infected for six months and to use a condom. He also said that a man must use a condom while having sex with a pregnant woman for the duration of her pregnancy.

If you have traveled to a country where Zika infection is prevalent but have remained asymptomatic, Fauci advises using a condom during sex for eight weeks.

See the full interview.

yahoo.com

Share RecommendKeepReplyMark as Last Read


To: donpat who wrote (6857)6/4/2016 11:11:03 PM
From: donpat
   of 12856
 
Rice University

eugeneseymourmd@mac.com
8:07 PM (3 hours ago)







to me


Dr. Ferrari was previously at Rice University

Dr. Diwan got his PhD there

The late Dr Richard Smalley was also at Rice when he won the Nobel Price for the invention of the “Bucky Balls”

Eugene Seymour MD MPH
Chief Executive Officer
NanoViricides, Inc
eugene@nanoviricides.com
www.nanoviricides.com
310-486-5677
"NNVC" on the New York Stock Exchange

Share RecommendKeepReplyMark as Last Read


From: donpat6/5/2016 10:06:21 AM
   of 12856
 
Characterization of CurcuEmulsomes: nanoformulation for enhanced solubility and delivery of curcumin


Figure 1Schematic drawing of CurcuEmulsome. CurcuEmulsome is composed of a solid tripalmitin core surrounded by phospholipid multi-layers. Thelipophilic load, i.e. curcumin, can locate itself in the inner core, as well as inside the phospholipid layers of the nanocarrier.

jnanobiotechnology.biomedcentral.com

Curry Compound Kills Cancer Cells



Kelly Dickerson


Dec. 5, 2013, 7:01 PM 18,173 13


Journal of Nanobiotechnology/Ucisik, Küpcü, Schuster, Sleytr
Curcumin being incorporated into emulsomes.

Scientists have found a very unusual potential cancer-fighting technique: nanoparticles that carry curry into cancer cells. Specifically the particles were filled with curcumin, a compound found in curry.

The research by scientists from the University of Natural Resources and Life Sciences in Austria was published in the Journal of Nanobiotechnology on Dec. 6.

Curcumin comes from the turmeric plant, which is commonly used in daals and other curries, and known for its distinctive bright yellow powder.

We already knew that curcumin works as an antioxidant and anti-inflammatory. Other research has shown that when curcumin is absorbed by tumor cells, it stops the cell's growth cycle eventually killing the cell.

The trick is getting the curcumin into the cancerous cells.

Curcumin does not easily dissolve in water, so cells are unlikely to absorb the compound on their own. That's why simply eating lots of curry won't fight cancer. So the researchers packed the curcumin into tiny fat blobs called emulsomes. Emulsomes have a solid core of fat surrounded by a lipid layer that cells absorb easily.

The researchers packed curcumin into the middle of these emulsomes and dubbed them "CurcuEmulsomes." They tested the effectiveness of CurcuEmulsomes by exposing them to cancer cells in the lab. The cells successfully absorbed the CurcuEmulsomes. As the outer emulsome dissolved, the curcumin was slowly and steadily released into the cells.

In the far right section of the graph below you can see how effective the CurcuEmulsomes were at killing the cancer cells. It took 48 hours to kill almost half of them when the curcumin was at the highest concentration level.

Journal of Nanobiotechnology/Ucisik, Küpcü, Schuster, SleytrThe graph shows the concentration of curcumin on the x-axis and the percentage of living cells on the y-axis. The left section of the graph is the control, the middle is free curcumin delivered to the cells, and the right is curcumin delivered by emulsomes.

The CurcuEmulsomes gradually releases the curcumin in the cells. This is advantageous because the curcumin isn't used up all at once; the cancerous cells have more time to absorb the curcumin, making it better able to kill more cells over time. That's better than giving the full dose all at once, which would give the cells time to recover before the next treatment.

The researchers now have to target the CurcuEmulsomes to cancerous cells inside the human body. In the meantime the research is a big step forward in the development of ways to administer other drugs that don't dissolve easily in water and which cells are unlikely to absorb.

businessinsider.com

Share RecommendKeepReplyMark as Last Read


From: donpat6/5/2016 10:19:13 AM
   of 12856
 
Trump’s Mission: It’s Hard to Be Great in the Middle of an Epidemic, So We Need a Cure Strategy

[SNIP]
Yet today, one sees green shoots of fresh thinking. For instance, Robert W. Patterson, the Republican challenger of a Democratic incumbent in New Jersey’s First Congressional District, has called for a Garden State enterprise zone for “fast-tracking the discovery of cures and vaccines for such diseases as Alzheimer’s and all forms of cancer.” (Hardcore BNN readers might recall that this idea of a Medical Cure Enterprise Zone was raised here, on April 10, 2014.)

Now, Patterson has taken the idea squarely into the political arena. As he said in a debate with his opponent on May 31:

Most Americans are more concerned about their health than they are about the care they receive. This process has to be fast-tracked. We need greater incentives so that this can happen.

breitbart.com

Share RecommendKeepReplyMark as Last Read


From: Straynut6/5/2016 2:35:46 PM
   of 12856
 
The true cost of Zika in the U.S. could be staggering

By ED LEEFELDT MONEYWATCH June 3, 2016, 5:30 AM
Last Updated Jun 3, 2016 5:12 PM EDT
While Congress continues to debate President Obama's proposal to spend $1.8 billion to fight the Zika virus, an unpleasant reality is beginning to surface. That figure could be insignificant compared to the total long-term cost if Zika runs rampant across the country this summer.
The warning signs are already here. The first "Zika baby" born in the continental U.S. at a Hackensack, New Jersey, hospital was diagnosed with a deformed head. There are 341 confirmed cases of Zika among pregnant women in the U.S. and its territories, according to the Centers for Disease Control and Prevention (CDC).
"The economic cost of Zika could be very high," said Dr. Peter Hotez, microbiologist at Texas Children's Hospital and dean of the National School of Tropical Medicine at Baylor College of Medicine.
Hotez will go before a closed session of the U.S. Senate on the morning of June 8 along with other top U.S. health officials to present the findings of their study of Zika, which focuses on the U.S. Gulf Coast. He said he couldn't be more specific about the potential impact of the disease until his congressional testimony.
No one, including the CDC, health insurers or those with the best handle on it, such as the Kaiser Family Foundation, seems prepared to go out on a limb and offer an estimate on the cost -- which could end up being abominably high ... or absurdly low.
P
This caution is admirable, but not helpful, when you consider what's at stake. Insurance companies estimate costs on the basis of past experience, and while Zika isn't a new virus, its probable connection with the birth defect microcephaly in newborns (abnormally small heads) has only recently come to light. Although the epidemic is now centered in Brazil, it's spreading around the world as the virus "hitchhikes" on migrating mosquitoes, travelers and possibly infected blood banks.
Brazil expects 2,500 cases of microcephaly this year, according to the World Health Organization (WHO). And with the active transmission of the virus throughout at least 62 countries and territories, including the Southern U.S. and Puerto Rico, carrying with it the danger of microcephaly for pregnant women, it's not surprising that Health and Human Services Secretary Sylvia Burwell warned that Zika "has the significant potential to affect ... the health of Americans."
But no one can predict how fast or far it will spread here. How many women in the first four to five months of pregnancy will be bitten by infected mosquitoes or be infected by sexual partners? Research has yet to show how long the virus remains in the body or whether the patient develops immunities after an initial bite.
Due to the lag between conception and birth, and since summer is the worst season for mosquitoes, many of these cases won't become known until fall or winter, when "clusters" could suddenly appear, particularly in areas that lack early detection of symptoms. Fetal abnormalities generally are detected six months after the initial infection, according to WHO.

Could these mosquitoes be largely wiped out by spraying? Right now there's no way to tell. CDC Director Dr. Thomas Frieden described this mosquito as "a sneaky cockroach" that can lay its eggs in a bottle cap and is a blood "sipper" that likes to bite multiple people, making it the ideal transmission vehicle.
A vaccine isn't an option until 2017 at the earliest, and it would probably be rushed with minimal testing. It's also possible that giving a vaccine to pregnant women might do more harm than good.
But two things are predictable. Without immediate forceful action, the Aedes aegypti mosquito -- which carries Zika and other dangerous viruses such as dengue fever, chikungunya and yellow fever -- will bite a lot of people, many of them poor and without window screens or access to full-time air conditioning.
In Puerto Rico, a likely hot spot for Zika this summer, estimates are that nearly a million people could be bitten and get the virus, many of them women who won't even know it before giving birth to a microcephalic child, depending on the quality of their medical care. If the mosquito and Zika epidemic aren't wiped out, one estimate is that 80 percent of the island could be vulnerable.
Avoiding pregnancy until the epidemic is over is one answer, but an estimated 20 percent of those who become pregnant there are high school girls. Preventing pregnancy in this group could prove harder than stopping Zika.

Children born with microcephaly, which has no cure, will require long-term care if they survive. Some microcephalics can live normal lives, but most suffer from severe disabilities. And while some could die early on from complications, a vast majority will need care throughout their lives.
In insurance lingo, this is referred to as a "long-tail" loss because the extent of the damage isn't known and is paid out over many years. For example, children with Down syndrome can live well into their 60s.
During a recent webinar for the Kaiser Family Foundation, the CDC's Frieden said the lifetime cost of care for a microcephalic child would be somewhere between $1 million and $10 million. Some of it would be borne by parents and relatives, but most of it would require the intervention of either private insurance or the public health care system. Many of these children would probably be institutionalized for at least part of their lives.
So here's the speculative -- and very speculative at that -- math. The Center for American Progress estimates that 2 million women in the U.S. will get pregnant this summer and fall, with nearly half of them living in areas potentially at risk of Zika. It's important to note that the public policy group's analysis isn't based on the actual prevalence of Zika around the country, while even if the virus spreads only a fraction of women are likely to be infected.
Still, if even just one in 10 gets Zika, the CDC estimates that up to 13 percent of their unborn offspring could develop microcephaly. If just 13,000 babies are born in the U.S. with this disability or to women who migrated here for better medical treatment, the cost of keeping them alive and providing for their lifetime care could range from $13 billion to as much as $130 billion.
But the saddest part of the equation is the much larger number of microcephalic children born abroad who will never have the money or resources to be kept alive.
© 2016 CBS Interactive Inc.. All Rights Reserved. webmail.myfairpoint.net

Share RecommendKeepReplyMark as Last ReadRead Replies (1)


From: Straynut6/5/2016 3:29:57 PM
   of 12856
 
By: DreamTeamNetwork
June 01, 2016 at 15:43 PM EDT

SeeThruEquity Conference Brings Together Microcap Companies and Investors in New York City

Yesterday, the 5th Annual SeeThruEquity Conference took place at Convene in New York City, connecting more than 30 presenting companies with microcap-focused investors, sponsors and industry professionals. The conference featured 30-minute presentations from each of the presenting companies, as well as opportunities for prospective investors to meet one-on-one with the companies’ management teams. In total, SeeThruEquity has hosted 20 investor conferences, attracting more than 4,400 investors and arranging over 1,800 one-on-one meetings.
SeeThruEquity’s quarterly investor conferences deliver considerable value to presenting companies, including an opportunity to speak to a high quality audience of institutional and sophisticated high-net worth investors. The independent research firm also initiates complimentary research coverage on all presenting companies, giving investors a more detailed look at the companies’ positions in their respective markets.

Health care beyond medical center walls
Sponsored by: Kaiser Permanente

Presenting companies at yesterday’s conference included:
3TL Technologies Corp. (OTCQB: TTMZF), Advanced Medical Isotope Corp. (OTC: ADMD), Amarantus Bioscience Holdings, Inc. (OTCQX: AMBS), Apivio Systems, Inc. (OTC: APVVF), Avant Diagnostics, Inc. (OTCQB: AVDX), BIO-key International, Inc. (OTCQB: BKYI), Blue Sphere Corp. (OTCQB: BLSP), Calmare Therapeutics Inc. (OTCQB: CTTC), Cellectar Biosciences, Inc. (NASDAQ: CLRB), Chineseinvestors.com, Inc. (OTCQB: CIIX), COPsync, Inc. (NASDAQ: COYN), DelMar Pharmaceuticals, Inc. (OTCQX: DMPI), Endonovo Therapeutics, Inc. (OTCQB: ENDV), General Employment Enterprises, Inc. (NYSE MKT: JOB), HealthWarehouse.com, Inc. (OTCQB: HEWA), HydroPhi Technologies Group, Inc. (OTC: HPTG), IEG Holdings Corp. (OTCQX: IEGH), International Western Petroleum, Inc. (OTCQB: INWP), NanoViricides, Inc. (NYSE MKT: NNVC), O2Micro International Ltd. (NASDAQ: OIIM), PAR Technology Corp. (NYSE: PAR), PCM, Inc. (NASDAQ: PCMI), Pivot Pharmaceuticals, Inc. (OTCQB: PVOTF), Predictive Technology Group, Inc. (OTC: PRED), Pressure BioSciences, Inc. (OTCQB: PBIO), Progressive Care, Inc. (OTC: RXMD), Rhino Resource Partners LP (OTCQB: RHNO), RiceBran Technologies (NASDAQ: RIBT), Staffing 360 Solutions, Inc. (NASDAQ: STAF), TapImmune, Inc. (OTCQB: TPIV), Yangtze River Development Ltd. (OTC: YERR)
The conference also included a panel on Regulation A+, the newly-revamped regulation that allows private companies to raise up to $50 million through unaccredited investor equity crowdfunding as an alternative to venture capital firms or other institutional capital providers. The panel was moderated by Brian Balbirnie and Michael Colon of Issuer Direct Corporation (NYSE MKT: ISDR), parent company of…
Read More >>
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. Through a full suite of investor relations and consultancy services, we help public companies develop and execute a strategic investor awareness plan as we’ve done for hundreds of others. Whether it’s capital raising, increasing awareness among the financial community, or enhancing corporate communications, we offer a variety of solutions to meet the objectives of our clients. For more information, visit www.MissionIR.com

Share RecommendKeepReplyMark as Last Read


To: Straynut who wrote (6871)6/5/2016 3:37:19 PM
From: donpat
   of 12856
 
It boggles the mind figuring out the lifetime cost for each Zika infected baby = $ Millions. Don't know the expected lifetime but the costs will make $1.9 Billion look puny by comparison.

Will the insurance industry pick up the tab? Will the gov??

Probably will BK the country.

And is there any solution???

Now??

Is ZikaCide of any assistance?

Does anybody give a damn?

Share RecommendKeepReplyMark as Last Read


From: donpat6/6/2016 9:05:34 AM
   of 12856
 
New material kills E. coli bacteria in 30 seconds

June 6, 2016


A microscopic image of the E. coli bacteria after it has been destroyed by the antimicrobial material. Credit: Institute of Bioengineering and Nanotechnology

Every day, we are exposed to millions of harmful bacteria that can cause infectious diseases, such as the E. coli bacteria. Now, researchers at the Institute of Bioengineering and Nanotechnology (IBN) of Agency for Science, Technology and Research (A*STAR), Singapore, have developed a new material that can kill the E. coli bacteria within 30 seconds. This finding has been published in the peer-reviewed journal, Small.

"The global threat of drug-resistant bacteria has given rise to the urgent need for new materials that can kill and prevent the growth of harmful bacteria. Our new antimicrobial material could be used in consumer and personal care products to support good personal hygiene practices and prevent the spread of infectious diseases," said IBN Executive Director, Professor Jackie Y. Ying.

Triclosan, a common ingredient found in many products such as toothpastes, soaps and detergents to reduce or prevent bacterial infections, has been linked to making bacteria resistant to antibiotics and adverse health effects. The European Union has restricted the use of triclosan in cosmetics, and the U.S. Food and Drug Administration is conducting an on-going review of this ingredient.

Driven by the need to find a more suitable alternative, IBN Group Leader Dr Yugen Zhang and his team synthesized a chemical compound made up of molecules linked together in a chain. Called imidazolium oligomers, this material can kill 99.7% of the E. coli bacteria within 30 seconds aided by its chain-like structure, which helps to penetrate the cell membrane and destroy the bacteria. In contrast, antibiotics only kill the bacteria without destroying the cell membrane. Leaving the cell structure intact allows new antibiotic-resistant bacteria to grow.

"Our unique material can kill bacteria rapidly and inhibit the development of antibiotic-resistant bacteria. Computational chemistry studies supported our experimental findings that the chain-like compound works by attacking the cell membrane. This material is also safe for use because it carries a positive charge that targets the more negatively charged bacteria, without destroying red blood cells," said Dr Zhang.

The imidazolium oligomers come in the form of a white powder that is soluble in water. The researchers also found that once this was dissolved in alcohol, it formed gels spontaneously. This material could be incorporated in alcoholic sprays that are used for sterilization in hospitals or homes.

E. coli is a type of bacteria found in the intestines of humans and animals, and some strains can cause severe diarrhea, abdominal pain and fever. Such infection is contagious and can spread through contaminated food or water, or from contact with people or animals. Good hygiene practices and proper food handling can prevent E. coli infections.

Besides E. coli, IBN's material was also tested against other common strains of antibiotic-resistant bacteria and fungi, such as Staphylococcus aureus, Pseudomonas aeruginosa and Candida albicans. These pathogens can cause conditions ranging from skin infections to pneumonia and toxic shock syndrome. Our material was able to kill 99.9% of these microbes within two minutes.

IBN's ultrafast bacteria-killing material could therefore be a potent new weapon against drug-resistant microbes.

Explore further: Daily dose of antibiotics helps bacteria develop multi-drug tolerance

More information: Siti Nurhanna Riduan et al. Ultrafast Killing and Self-Gelling Antimicrobial Imidazolium Oligomers, Small(2016). DOI: 10.1002/smll.201600006

Journal reference: Small

Provided by: Agency for Science, Technology and Research (A*STAR), Singapore

Read more at: phys.org

Share RecommendKeepReplyMark as Last ReadRead Replies (1)


To: donpat who wrote (6874)6/6/2016 9:56:58 AM
From: drkaz
   of 12856
 
Interesting,.... although I wonder how far they have gone to see if it has toxic effects on animal or plant cell membranes.

As a surface disinfectant - it may be wonderful stuff regardless - but if it cannot be used directly on hands or on patient tissues, it may limit some of its potential utility.

Share RecommendKeepReplyMark as Last ReadRead Replies (1)


To: drkaz who wrote (6875)6/6/2016 10:08:30 AM
From: donpat
   of 12856
 
True - why not try it internally - what's to lose!

To me it seems clear - try!

BWDIK - Some of the most wondrous things happen when those who don't know go ahead and try while the 'smart' know better and do not!

Share RecommendKeepReplyMark as Last Read
Previous 10 Next 10